Table 4.
Improvement in EQ-5D health-related quality of life dimensions
| Eluvia | Zilver PTX | Difference [95% CI] | p | |
|---|---|---|---|---|
| 1 Month | ||||
| Mobility | 48.2% (27/56) | 35.7% (10/28) | 12.5% [− 9.6%, 34.6%] | 0.28 |
| Self-care | 1.8% (1/56) | 3.6% (1/28) | − 1.8% [− 9.5%, 5.9%] | 1.00a |
| Usual activities | 19.6% (11/56) | 35.7% (10/28) | − 16.1% [− 36.6%, 4.5%] | 0.11 |
| Pain/discomfort | 44.6% (25/56) | 39.3% (11/28) | 5.4% [− 16.9%, 27.6%] | 0.64 |
| Anxiety/depression | 10.7% (6/56) | 17.9% (5/28) | − 7.1% [− 23.5%, 9.2%] | 0.49a |
| 6 Months | ||||
| Mobility | 48.2% (27/56) | 21.4% (6/28) | 26.8% [6.7%, 46.8%] | 0.02 |
| Self-care | 1.8% (1/56) | 0.0% (0/28) | 1.8% [− 1.7%, 5.3%] | 1.00a |
| Usual activities | 19.6% (11/56) | 32.1% (9/28) | − 12.5% [− 32.7%, 7.7%] | 0.20 |
| Pain/discomfort | 41.1% (23/56) | 28.6% (8/28) | 12.5% [− 8.6%, 33.6%] | 0.26 |
| Anxiety/depression | 8.9% (5/56) | 21.4% (6/28) | − 12.5% [− 29.4%, 4.4%] | 0.17a |
| 12 Months | ||||
| Mobility | 40.0% (22/55) | 22.2% (6/27) | 17.8% [− 2.6%, 38.1%] | 0.11 |
| Self-care | 1.8% (1/55) | 0.0% (0/27) | 1.8% [− 1.7%, 5.3%] | 1.00a |
| Usual activities | 20.0% (11/55) | 33.3% (9/27) | − 13.3% [− 34.0%, 7.4%] | 0.19 |
| Pain/discomfort | 47.3% (26/55) | 25.9% (7/27) | 21.3% [0.2%, 42.5%] | 0.06 |
| Anxiety/depression | 10.9% (6/55) | 11.1% (3/27) | − 0.2% [− 14.6%, 14.2%] | 1.00a |
| 24 Months | ||||
| Mobility | 40.8% (20/49) | 27.3% (6/22) | 13.5% [− 9.6%, 36.7%] | 0.27 |
| Self-care | 4.1% (2/49) | 4.5% (1/22) | − 0.5% [− 10.8%, 9.9%] | 1.00a |
| Usual activities | 14.3% (7/49) | 31.8% (7/22) | − 17.5% [−39.3%, 4.3%] | 0.11a |
| Pain/discomfort | 38.8% (19/49) | 40.9% (9/22) | − 2.1% [− 26.8%, 22.5%] | 0.86 |
| Anxiety/depression | 12.2% (6/49) | 18.2% (4/22) | − 5.9% [− 24.5%, 12.6%] | 0.49a |
ap-values from 2-sided Fisher’s exact test